Source: Molec Aspects Med. 1994; 15:S165-S175.

Abstract:

Over an eight year period (1985-1993), we treated 424 patients with various forms of cardiovascular disease by adding coenzyme Q10 (CoQ10) to their medical regimens. Doses of CoQ10 ranged from 75 to 600 mg/day by mouth (average 242 mg). Treatment was primarily guided by the patient's clinical response.

In many instances, CoQ10 levels were employed with the aim of producing a whole blood level greater than or equal to 2.0 µg/ml (average 2.92 µg/ml, n=297). Patients were followed for an average of 17.8 months, with a total accumulation of 632 patient years. Eleven patients were omitted from this study: 10 due to non-compliance and one who experienced nausea. Eighteen deaths occurred during the study period with 10 attributable to cardiac causes.

Patients were divided into six diagnostic categories: ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), primary diastolic dysfunction (PDD), hypertension (HTN), mitral valve prolapse (MVP)

and valvular heart disease (VHD). For the entire group and for each diagnostic category, we evaluated clinical response according to the New York Heart Association (NYHA) functional scale, and found significant improvement.

Of 424 patients, 58 per cent improved by one NYHA class, 28% by two classes and 1.2% by three classes.

A statistically significant improvement in myocardial function was documented using the following echocardiographic parameters: left ventricular wall thickness, mitral valve inflow slope and fractional shortening.

Before treatment with CoQ10, most patients were taking from one to five cardiac medications. During this study, overall medication requirements dropped considerably: 43% stopped between one and three drugs.

No apparent side effects from CoQ10 treatment were noted other than a single case of transient nausea.

In conclusion, CoQ10 is a safe and effective adjunctive treatment for a broad range of cardiovascular diseases, producing gratifying clinical responses while easing the medical and financial burden of multidrug therapy.

References

Hans R. Larsen, MSc ChE. Coenzyme Q10: The Wonder Nutrient.

International Journal of Alternative and Complementary Medicine, Vol.

16, No 2, February 1998, pp. 11-12.

Littarru, Gian Paolo, et al. Clinical aspects of coenzyme Q: Improvement of cellular bioenergetics or antioxidant protection? In Handbook of Antioxidants, eds. Enrique Cadenas and Lester Packer, NY, Marcel Dekker, Inc., 1996, pp. 203-39

PETER H. LANGSJOEN, M.D., F.A.C.C.

INTRODUCTION TO COENZYME Q10

Murray, Michael T. Encyclopedia of Nutritional Supplements,

Rocklin, CA, Prima Publishing, 1996, pp. 296-308

Research on coenzyme Q10 in clinical medicine and in immunomodulation.

Drugs Exp Clin Res (SWITZERLAND) 1985, 11 ( p539-45 Kendler BS.

Recent nutritional approaches to the prevention and therapy of cardiovascular disease.

Prog Cardiovasc Nurs 1997 Summer;12(3):3- 23 Kendler BS.

Nutritional strategies in cardiovascular disease control: an update on vitamins and conditionally essential nutrients. Prog Cardiovasc Nurs 1999 Autumn;14(4):124-9 Greenberg, Steven and Frishman, William H. Co-enzyme Q10: A new drug for cardiovascular disease. Journal of Clinical Pharmacology, Vol. 30, 1990, pp. 596-608

Hanaki, Yoshihiro, et al. Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factor. New England Journal of Medicine, Vol. 325, September 12, 1991, pp. 814-15 Baggio, E., et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Molec. Aspects Med., Vol. 15 (suppl), 1994, pp. S287-94

Oda, T. Coenzyme Q10 therapy on the cardiac dysfunction in patients with mitral valve prolapse. Dose vs effect and dose vs serum level of coenzyme Q10. In Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, eds.

Folkers, K. and Yamamura, Y., Amsterdam, Elsevier, 1986, pp. 269-80 Langsjoen, P., et al. Treatment of essential hypertension with coenzyme Q10. Molec. Aspects Med., Vol. 15 (suppl), 1994, pp. S265-72

McCarty MF. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypotheses 1999 Oct;53(4):300- 4 Vanfraechem, J.H.P. and Folkers, K. Coenzyme Q10 and physical performance. In Biomedical and Clinical Aspects of Coenzyme Q, Vol. 3, eds.

Folkers, K. and Yamamura, Y., Amsterdam, Elsevier, 1981, pp. 235- 41 Folkers, K., et al. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochemical and Biophysical Research Communications, Vol. 193, May 28, 1993, pp. 88-92

Littarru, G.P., et al. Deficiency of coenzyme Q10 in gingival tissue from patients with periodontal disease. Proceedings of the National Academy of Sciences USA, Vol. 68, 1971, p. 2332

Lockwood, K., et al. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochemical and Biophysical Research Communications, Vol. 199, 1994, pp. 1504-08

Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000 Apr;5(2):93-108 Mindell, Earl. Earl Mindell's Vitamin Bible, NY, Warner Books, 1991, p. 289

You might like to read:

• CoEnzyme Q10 and Severe Headaches
• CoEnzyme Q10 and Heart, High Blood Pressure, Diabetes and Infertility